• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.

    5/13/25 11:07:50 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Biofrontera Inc.

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)


    09077D209

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09077D209


    1Names of Reporting Persons

    Rosalind Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ONTARIO, CANADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,886,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,886,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,886,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  This percentage is calculated based upon 8,873,932 common stock as of January 15, 2025, as reported by the Issuer on the S1 filed on January 17, 2025. However, as more fully described in Item 4, the securities reported in rows 6, 8 and 9 show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8 and 9. (6) 644,393 shares of Common Stock 6,586,629 shares of Common Stock issuable upon exercise of preferred shares 2,655,947 shares of Common Stock issuable upon exercise of convertible debt


    SCHEDULE 13G

    CUSIP No.
    09077D209


    1Names of Reporting Persons

    SALAMON STEVEN A J
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ONTARIO, CANADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,886,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,886,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,886,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (6) 644,393 shares of Common Stock 6,586,629 shares of Common Stock issuable upon exercise of preferred shares 2,655,947 shares of Common Stock issuable upon exercise of convertible debt


    SCHEDULE 13G

    CUSIP No.
    09077D209


    1Names of Reporting Persons

    Aharon Gil
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ONTARIO, CANADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,886,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,886,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,886,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (6) 644,393 shares of Common Stock 6,586,629 shares of Common Stock issuable upon exercise of preferred shares 2,655,947 shares of Common Stock issuable upon exercise of convertible debt


    SCHEDULE 13G

    CUSIP No.
    09077D209


    1Names of Reporting Persons

    Rosalind Master Fund L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,886,969.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,886,969.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,886,969.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (6) 644,393 shares of Common Stock 6,586,629 shares of Common Stock issuable upon exercise of preferred shares 2,655,947 shares of Common Stock issuable upon exercise of convertible debt


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Biofrontera Inc.
    (b)Address of issuer's principal executive offices:

    120 PRESIDENTIAL WAY,, 120 PRESIDENTIAL WAY,, WOBURN, MASSACHUSETTS, 01801.
    Item 2. 
    (a)Name of person filing:

    Rosalind Advisors, Inc. Advisor to RMF Rosalind Master Fund L.P. RMF Steven Salamon President Steven Salamon is the portfolio manager of the Advisor which advises RMF. Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.
    (b)Address or principal business office or, if none, residence:

    Rosalind Advisors, Inc. 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada Rosalind Master Fund L.P. P.O. Box 309 Ugland House, Grand Cayman KY1-1104, Cayman Islands Steven Salamon 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada Gilad Aharon 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada
    (c)Citizenship:

    Mr. Salamon and Mr. Aharon are citizens of Canada, resident in Ontario
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP No.:

    09077D209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information as of the date of the event which requires filing of this statement required by Items 4(a) to (c) is set forth in Rows 5 to 12 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 8,873,932 common stock as of January 15, 2025, as reported by the Issuer on the S1 filed on January 17, 2025. Rosalind Master Fund L.P. may have been deemed to have the beneficial ownership of 644,393 shares of common stock representing the beneficial ownership of approximately 7.26% of the common stocks as mentioned above, which excludes the 9,242,576 shares issuable upon the exercise of preferred shares and convertible debt because they contain a blocker provision under which the holder thereof does not have the right to exercise any of the preferred shares/convertible debt to the extent that such exercise would result in beneficial ownership by the holder in excess of 9.99% of the Common Stock. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of the preferred shares/convertible debt due to the Blockers. Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.
    (b)Percent of class:

    Rosalind Advisors, Inc. 9.9% Rosalind Master Fund L.P. 9.9% Steven Salamon 9.9% Gilad Aharon 9.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    Rosalind Advisors, Inc. 644,393 Rosalind Master Fund L.P. 644,393 Steven Salamon 644,393 Gilad Aharon 644,393

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    Rosalind Advisors, Inc. 644,393 Rosalind Master Fund L.P. 644,393 Steven Salamon 644,393 Gilad Aharon 644,393

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rosalind Advisors, Inc.
     
    Signature:Steven Salamon
    Name/Title:President
    Date:05/13/2025
     
    SALAMON STEVEN A J
     
    Signature:Steven Salamon
    Name/Title:Steven Salamon
    Date:05/13/2025
     
    Aharon Gil
     
    Signature:Gil Aharon
    Name/Title:Gil Aharon
    Date:05/13/2025
     
    Rosalind Master Fund L.P.
     
    Signature:Mike McDonald
    Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
    Date:05/13/2025
    Get the next $BFRI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFRI

    DatePrice TargetRatingAnalyst
    12/15/2021$11.00Buy
    Benchmark
    11/24/2021$20.00Buy
    Roth Capital
    More analyst ratings

    $BFRI
    Financials

    Live finance-specific insights

    See more
    • Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

      Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent weeks included the following: Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase from the same period of the prior year.Cash and cash equivalents were $1.8 million as of March 31, 2025, compared with $5.9 million on December 31, 2024.Announce

      5/15/25 5:09:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

      Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase from $34.1 million in 2023 with Q4 2024 growing 18.5% over Q4 2023. The growth was primarily driven by increases in Ameluz® sales volume and unit price, and the successful launch of our RhodoLED® XL Lam

      3/21/25 8:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

      WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Call and Webcast Information DateFriday, March 21, 2025Time10:00 AM Eastern TimeDial In Numbers1-877-877-1275 (U.S.)1-412-858-5202 (international)WebcastFourth Quarter and FY 2024 Financial Results a

      3/11/25 10:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

      SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

      11/14/24 3:54:03 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

      SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

      11/14/24 1:13:39 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

      SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

      11/13/24 2:12:35 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

      Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information.Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection. WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol

      6/3/25 2:30:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

      Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent weeks included the following: Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase from the same period of the prior year.Cash and cash equivalents were $1.8 million as of March 31, 2025, compared with $5.9 million on December 31, 2024.Announce

      5/15/25 5:09:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

      The initiative is a social media challenge ahead of Global AK Awareness Day, on May 24, which supports the work of The Skin Cancer Foundation and EuromelanomaThe Hats On Challenge provides an opportunity to take part in raising awareness of AK.Actinic Keratosis (AK) is a rough, scaly patch on the skin caused by years of sun exposure. If left untreated, AK can develop into squamous cell carcinoma, a type of skin cancer. Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), and Almirall, a global pharmaceutical company dedicated to medical dermatology an

      5/1/25 2:38:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BFRI
    SEC Filings

    See more

    $BFRI
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 4 filed by Director Weber Kevin Daniel

      4 - Biofrontera Inc. (0001858685) (Issuer)

      7/16/24 7:52:14 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lanckriet Heikki

      4 - Biofrontera Inc. (0001858685) (Issuer)

      7/16/24 7:52:13 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Leffler Eugene Frederick

      4 - Biofrontera Inc. (0001858685) (Issuer)

      7/16/24 7:52:11 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Biofrontera Inc. (0001858685) (Filer)

      6/3/25 5:15:02 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFR14A filed by Biofrontera Inc.

      DEFR14A - Biofrontera Inc. (0001858685) (Filer)

      6/3/25 5:11:21 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Biofrontera Inc.

      8-K - Biofrontera Inc. (0001858685) (Filer)

      5/23/25 4:30:14 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

      WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over

      8/29/23 8:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

      WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o

      7/12/23 8:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Announces Resignation of CEO

      Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial GoalsWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera's Executive Chairman and founder, will assume the CEO responsibilities. Ms. Monaco intends to pursue other professional opportunities and her resignation did not res

      5/12/23 7:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on Biofrontera with a new price target

      Benchmark initiated coverage of Biofrontera with a rating of Buy and set a new price target of $11.00

      12/15/21 6:49:18 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Biofrontera with a new price target

      Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00

      11/24/21 8:02:09 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care